Hepatorenal Syndrome Clinical Trial
Official title:
A Multi-Center, Double-Blind, Randomized, Controlled Study to Determine the Safety and Pharmacokinetics of Ifetroban Injection in Hepatorenal Syndrome
Verified date | February 2017 |
Source | Cumberland Pharmaceuticals |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
A study of ifetroban in the treatment of hepatorenal syndrome (HRS) in hospitalized adult patients to assess the safety and pharmacokinetics of 3 days of intravenous ifetroban.
Status | Completed |
Enrollment | 55 |
Est. completion date | July 2015 |
Est. primary completion date | June 2015 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: 1. Chronic liver disease, defined as cirrhosis with ascites based on clinical findings (biopsy not necessary). 2. Subjects with either Type 1 or Type 2 HRS defined in a and b below: a. Type 1: i. At least a doubling of the serum creatinine to a minimum of 220 µmol/L (2.5 mg/dL) at enrollment, occurring over a period of less than 14 days, OR ii. A 50% or greater reduction in the estimated glomerular filtration rate (GFR - calculated by the method of Cockcroft-Gault) to below 20 mL/min at enrollment occurring over a period of less than 14 days. iii. A projected doubling of serum creatinine to a minimum of 2.5 mg/dL, expected to occur in less than 14 days based on the rate of change observed. b. Type 2: defined as at least a 33% reduction in creatinine clearance occurring over a period of greater than 2 weeks, with a serum creatinine (SCr) > 133µmol/L (1.5 mg/dL). 3. Oliguria occurring within 48 hours prior to the first administration CTM. Oliguria is defined as an average urine output of < 35 mL/hr (measured for a minimum of 4 hours) under either of the following circumstances: a. When measured central venous pressure (CVP) > 12 mmHg, OR b. following a fluid challenge consisting of either: i. at minimum 20 mL/kg isotonic fluid (e.g. any combination of 5% albumin, normal saline, blood or blood products) given over no more than 6 hours ii. at minimum 1 g/kg of hypertonic fluid (e.g. 25% albumin) given over no more than 24 hours iii. an equivalent combination of 3.b.i and 3.b.ii Exclusion Criteria: 1. History of allergy or hypersensitivity to ifetroban 2. Pregnant or nursing 3. Less than 18 years of age 4. Serum creatinine at the time of enrollment greater than or equal to 5.0 mg/dL 5. Platelet count at screening less than 30 x 10^3 platelets/µL 6. Anticipated of planned need for dialysis within 5 days of first CTM dose. 7. Active gastrointestinal hemorrhage (where active is defined as evidence of bleeding within 48 hours of the first dose of CTM) 8. Evidence of current (within past 30 days) obstructive (post-renal) or intrinsic renal disease [including but not limited to: acute tubular necrosis (ATN), glomerular diseases/glomerulonephritis, acute interstitial nephritis (AIN), known urinary obstruction, proteinuria > 500 mg/day, microhematuria (> 50 RBCs/high power field), abnormal renal ultrasound, fractional excretion of sodium (FeNa) > 2.0%, any urinary casts other than hyaline. 9. Current or recent (within the preceding 5 days) treatment with nephrotoxic drugs including but not limited to: NSAIDs (prior 48 hours), angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARB), calcineurin inhibitors (cyclosporine, tacrolimus), aminoglycosides, amphotericin B, antiretrovirals and antivirals (adefovir, cidofovir, tenofovir, acyclovir, indinavir), cisplatin, methotrexate, cyclosporine, amphotericin B contrast agents, foscarnet, zoledronate, etc. 10. Presence of shock defined as hypotension, with a mean arterial pressure less than 50 mmHG. 11. New York Heart Association class 3 or 4 heart failure. 12. Presence of hepatocellular carcinoma not transplantable by Milan criteria 13. Cardiopulmonary arrest without full recovery of mental status 14. Moribund and death expected within five days 15. Bacterial or fungal infections which have been unresponsive to at least 24 hours of appropriate antimicrobial therapy 16. Burns > 30% body surface area 17. Exposed to investigational drugs within 30 days before 1st CTM administration. 18. Inability to understand the requirements of the study. (Subjects must be willing to provide written informed consent or consent of legally recognized representative, as evidenced by signature on an informed consent document approved by an Institutional Review Board [IRB], and agree to abide by the study restrictions. If the subject is incapacitated, informed consent will be sought from a legally recognized representative). 19. Refusal to provide written authorization for use and disclosure of protected health information. 20. Be otherwise unsuitable for the study, in the opinion of the Investigator. |
Country | Name | City | State |
---|---|---|---|
India | MIDAS Multispeciality Hospital PVT LTD | Nagpur | Maharashtra |
United States | University of Michigan Hospital | Ann Arbor | Michigan |
United States | Emory University Hospital | Atlanta | Georgia |
United States | The Ohio State University | Columbus | Ohio |
United States | Baylor All Saints Medical Center | Fort Worth | Texas |
United States | Indiana University (Division of Gastroenterology/Hepatology) | Indianapolis | Indiana |
United States | UCSD, Hillcrest Medical Center Hospital | La Jolla | California |
United States | NYU Langone Medical Center | New York | New York |
United States | Mayo Clinic - Arizona | Phoenix | Arizona |
United States | Virginia Commonwealth University | Richmond | Virginia |
United States | University of Utah Health Sciences Center | Salt Lake City | Utah |
United States | UCSF (University of California-San Francisco) | San Francisco | California |
Lead Sponsor | Collaborator |
---|---|
Cumberland Pharmaceuticals |
United States, India,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Half-life (T-1/2) of Ifetroban and Ifetroban Acylglucuronide | Plasma concentrations of ifetroban and its major active metabolite were measured at Baseline and Study Hours 1, 2, 4, 8, 12, 24, 48, 49, 50, 52, 56, 60, and 72 to determine the Pharmacokinetic parameters. | 3 days | |
Primary | Pharmacokinetic Parameters (Exposure) of Ifetroban and Ifetroban Acylglucuronide After Three Days of Treatment | Plasma concentrations of ifetroban and its primary active metabolite were measured at Baseline and Study Hours 1, 2, 4, 8, 12, 24, 48, 49, 50, 52, 56, 60, and 72 to determine the Pharmacokinetic parameters. | 3 days | |
Primary | Pharmacokinetic Parameters (Concentration) of Ifetroban and Ifetroban Acylglucuronide After Three Days of Treatment | Plasma concentrations of ifetroban and it's major active metabolite were measured at Baseline and Study Hours 1, 2, 4, 8, 12, 24, 48, 49, 50, 52, 56, 60, and 72 to determine the Pharmacokinetic parameters. | 3 days | |
Secondary | Safety: Day 28 Mortality | 28 days | ||
Secondary | Percentage of Patients Achieving a Treatment-period Serum Creatinine Reduction Below 1.5 mg/dL | Day 0 through Day 5 | ||
Secondary | The Percentage of Patients Achieving a Reduction of Creatinine Clearance to Below Baseline on Two Consecutive Daily Measurements | Day 0 to Day 5 | ||
Secondary | Change in 24-hour Urine Volume | The volume of urine collected in a 24-hour post-treatment period minus the volume collected in a 24-hour pre-treatment period. | Baseline to Hour 96 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00370253 -
Noradrenalin vs Terlipressin in Hepatorenal Syndrome
|
Phase 3 | |
Completed |
NCT00359853 -
Norfloxacin In The Primary Prophylaxis Of Spontaneous Bacterial Peritonitis
|
Phase 4 | |
Completed |
NCT01143246 -
A Placebo-Controlled, Double-Blind Study to Confirm the Reversal of Hepatorenal Syndrome Type 1 With Terlipressin
|
Phase 3 | |
Recruiting |
NCT05346393 -
HRS-AKI Treatment With TIPS in Patients With Cirrhosis
|
N/A | |
Terminated |
NCT00742339 -
Terlipressin + Albumin Versus Midodrine + Octreotide in the Treatment of Hepatorenal Syndrome
|
Phase 2/Phase 3 | |
Terminated |
NCT00734136 -
Role Of Angiogenic Factors In The Development Of Hepatorenal Syndrome
|
N/A | |
Recruiting |
NCT06095440 -
A Retrospective Analysis of Outcomes in Patients With Hepatorenal Syndrome at Methodist Dallas Medical Center
|
||
Completed |
NCT02097784 -
Interest of the Echocardiography in the Management of Cirrhotic Patients With Acute Kidney Injury
|
N/A | |
Recruiting |
NCT04898010 -
The Selective Cytopheretic Device (SCD) for Acute Kidney Injury (AKI) and Hepatorenal Syndrome (HRS) Type I
|
N/A | |
Recruiting |
NCT05875948 -
Study to Evaluate R2R01 Plus Terlipressin Versus Terlipressin Alone in Patients With Hepatorenal Syndrome
|
Phase 2 | |
Completed |
NCT04416282 -
Efficacy of Early Terlipressin Plus Albumin Therapy in Comparison to Standard Treatment for HRS-AKI in Acute-on-chronic Liver Failure.
|
N/A | |
Recruiting |
NCT02049125 -
Study of Accuracy of NGAL, a Renal Injury Biomarker, in Patients With Cirrhosis
|
N/A | |
Completed |
NCT00764049 -
Single Pass Albumin Dialysis in Patients With Cirrhosis
|
Phase 1/Phase 2 | |
Completed |
NCT00089570 -
Study of Terlipressin Versus Placebo to Treat Hepatorenal Syndrome Type 1
|
Phase 3 | |
Withdrawn |
NCT01587222 -
Midodrine, Octreotide and Albumin: Impact on Renal Function of Patients With Liver Cirrhosis and Renal Failure
|
Phase 2 | |
Recruiting |
NCT02489864 -
The Effect of Terlipressin in the Prevention of Type 2 Hepatorenal Syndrome by Improving Mean Arterial Pressure
|
Phase 4 | |
Recruiting |
NCT02434445 -
Use of Novel Plasma and Urinary Biomarkers to Predict the Development of Hepatorenal Syndrome in Cirrhotic Patients
|
N/A | |
Completed |
NCT02770716 -
Study To Confirm Efficacy and Safety of Terlipressin in Hepatorenal Syndrome (HRS) Type 1
|
Phase 3 | |
Completed |
NCT05387811 -
International Registry of Acute Kidney Injury in Cirrhosis: The GLOBAL AKI Project
|
||
Withdrawn |
NCT04048707 -
Angiotensin 2 for Hepatorenal Syndrome
|
Phase 2 |